Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Mandeville K, Valentic M, Ivankovic D, Pristas I, Long J, Patrick H. Quality assurance of registries for health technology assessment. Int J Technol Assess Health Care. 2018;34(4):360-7.
Poulos C, Kinter E, Van Beek J, Christensen K, Posner J. Preferences of patients with multiple sclerosis for attributes of injectable multiple sclerosis treatments in the United Kingdom and France. Int J Technol Assess Health Care. 2018 Jan;34(4):425-33. doi: 10.1017/S0266462318000491
Basarir H, Brennan A, Jacques R, Pollard D, Stevens K, Freeman J, Wales J, Price K. Cost-effectiveness of structured education in children with type-1 diabetes mellitus. Int J Technol Assess Health Care. 2016 Jan;32(4):203-11.
Moloney R, Mohr P, Hawe E, Shah K, Garau M, Towse A. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. Int J Technol Assess Health Care. 2015 Jan;31(1-2):90-8. doi: 10.1017/S0266462315000203
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Ara R, Basarir H, Keetharuth AD, Barbieri M, Weatherly HL, Sculpher MJ, Ahmed H, Brown S. Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review. Int J Technol Assess Health Care. 2014 Oct;30(4):381-93. doi: 10.1017/S0266462314000531
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013 Jan 1;29(1):92-100.
Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.
Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care. 2003 Mar;19(2):396-406.
Arana JI, Jarén C, Arana A, Arazuri S. Pruebas diagnósticas en la clasificación de productos agrícolas. Horticultura. 2001;19:20-6.
Bonfill X, Marzo M, Sentís M, Rossell M, Gallardo X, Rivero E. Evaluation of the regular practice of breast cancer screening in a health area. Int J Technol Assess Health Care. 1996 Apr;12(2):388-94.